Condition (MeSH)
HTLV-I Infections
ClinicalTrials.gov lists 31 trials for HTLV-I Infections or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 31 trials are tagged with HTLV-I Infections itself; the rest are tagged with a narrower condition beneath it.
When did HTLV-I Infections trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 5 |
| 2013 | 2 |
| 2012 | 1 |
| 2011 | 2 |
| 2009 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are HTLV-I Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 3 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 4 |
| Observational | 7 |
How many HTLV-I Infections trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 18 |
| Terminated | 6 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most HTLV-I Infections trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 6 |
| MP Biomedicals, LLC | 3 |
| National Cancer Institute (NCI) | 3 |
| Kyowa Kirin Co., Ltd. | 1 |
| Tanabe Pharma Corporation | 1 |
Which drugs are being tested for HTLV-I Infections? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Valproic acid, sodium salt | 3 |
| Lamivudine-Zidovudine (3TC-ZDV) | 1 |
| Positron Emission Tomography (PET) | 1 |
| Dolutegravir Pill | 1 |
| Interferon Alfa-2B | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do HTLV-I Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 4 | 2 |
| Hypercalcemia | 4 | 3 |
| Sepsis | 3 | 2 |
| Aspartate aminotransferase increased | 2 | 1 |
| Fever | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover HTLV-I Infections? (55)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. | Pathogens (Basel, Switzerland) | 2024 | Yes |
| KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target. | Blood | 2022 | Yes |
| Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent. | The Lancet. Infectious diseases | 2021 | Yes |
| Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil. | PloS one | 2020 | Yes |
| CT Chest and pulmonary functional changes in patients with HTLV-associated myelopathy in the Eastern Brazilian Amazon. | PloS one | 2017 | Yes |
Showing 5 of 55 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.